Cirrhosis of the liver
302 results
201 - 300
Antioxidant supplements for non‐alcoholic fatty liver disease and/or steatohepatitis- Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Cochrane systematic review
- Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infection
- Lifestyle modifications for nonalcohol‐related fatty liver disease: a network meta‐analysis
- Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: Cochrane systematic review
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
- Bile acids for primary sclerosing cholangitis: Cochrane systematic review
Hyponatraemia - Hernias in adults
- Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation: Cochrane systematic review
- Ursodeoxycholic acid for cystic fibrosis‐related liver disease
- Bariatric surgery for non‐alcoholic steatohepatitis in obese patients
- Viral hepatitis
- Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma
- Glucocorticosteroids for people with alcoholic hepatitis: Cochrane systematic review
- Interferon for interferon naive patients with chronic hepatitis C: Cochrane systematic review
- Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
- Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis: Cochrane systematic review
- Hepatitis B vaccination during pregnancy for preventing infant infection: Cochrane systematic review
- Magnesium for skeletal muscle cramps
- Warfarin therapy
- Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C
- Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD)
- Bile acids for viral hepatitis
- Pharmacological interventions for primary sclerosing cholangitis
- Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis
- Bicyclol for chronic hepatitis B
- Pharmacological interventions for acute hepatitis C infection
- Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis
- Bicyclol for chronic hepatitis C
- Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus
- Vitamin D supplementation for chronic liver diseases in adults
Human albumin infusions improve mortality in patients with persistent ascites (ANSWER)- Biomarkers for diagnosis of Wilson's disease
- Interventions for hereditary haemochromatosis
- Prevention of venous thromboembolism
- Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma: Cochrane systematic review
- Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease
- Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease
- Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease
- Peptic ulcer disease, Helicobacter pylori infection and chronic gastritis
- Nutritional support for liver disease
- Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B
- Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults
- Direct oral anticoagulants
- Platelet count, spleen length, and platelet count‐to‐spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis
- Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients
- PEG better and faster than lactulose for initial treatment of hepatic encephalopathy
- Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis
- Human albumin infusion for treating oedema in people with nephrotic syndrome
- Acetyl‐L‐carnitine for patients with hepatic encephalopathy
- Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome
- Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C
- Interventions for dialysis patients with hepatitis C virus (HCV) infection
- Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis
- Pharmacological interventions for acute hepatitis B infection
- Entecavir for children and adults with chronic hepatitis B
- Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia
- Acupuncture for chronic hepatitis B
- Palliative treatment
- Somatostatin analogues for acute bleeding oesophageal varices
- Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B
- Management of people with intermediate‐stage hepatocellular carcinoma
- Nitazoxanide for chronic hepatitis C
- Aminoadamantanes versus other antiviral drugs for chronic hepatitis C: Cochrane systematic review
- Magnesium for skeletal muscle cramps
- Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
- Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B
- Pruritus
- Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia
- Diverticulitis and diverticulosis
- Management of people with early‐ or very early‐stage hepatocellular carcinoma
- Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients
- Recognition of alcohol and drug abuse
- Pharmacological treatment of depression
- Banding ligation versus beta‐blockers for primary prevention in oesophageal varices in adults
- Interventions for chronic non-hypovolaemic hypotonic hyponatraemia: Cochrane systematic review
- Preoperative assessment
- Unintentional weight loss in adults
- Branched‐chain amino acids for people with hepatic encephalopathy
- Combined pharmacological and psychosocial interventions for alcohol use disorder
- Drugs for treating Schistosoma mansoni infection